{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:46:04Z","timestamp":1761630364093},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T00:00:00Z","timestamp":1104451200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1007\/s00296-004-0542-1","type":"journal-article","created":{"date-parts":[[2004,12,30]],"date-time":"2004-12-30T12:42:26Z","timestamp":1104410546000},"page":"209-214","source":"Crossref","is-referenced-by-count":55,"title":["Anti-TNF\u03b1 therapy in rheumatoid arthritis and autoimmunity"],"prefix":"10.1007","volume":"26","author":[{"given":"Paola","family":"Caramaschi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Biasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Colombatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pieropan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa Maria","family":"Pacor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Maria","family":"Bambara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,12,31]]},"reference":[{"key":"542_CR1","first-page":"2513","volume":"29","author":"HE Paulus","year":"2002","unstructured":"Paulus HE, Wiesner J, Bulpitt KJ, Patnaik M, Law J, Park GS, Wong WK (2002) Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment. J Rheumatol 29:2513\u20132520","journal-title":"J Rheumatol"},{"key":"542_CR2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/art.10876","volume":"48","author":"L Rycke De","year":"2003","unstructured":"De Rycke L, Kruithof E, Van Demme N, Hoffman IEA, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F (2003) Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum 48:1015\u20131023","journal-title":"Arthritis Rheum"},{"key":"542_CR3","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","volume":"43","author":"PJ Charles","year":"2000","unstructured":"Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor \u03b1. Arthritis Rheum 43:2383\u20132390","journal-title":"Arthritis Rheum"},{"key":"542_CR4","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/art.11104","volume":"48","author":"J Braun","year":"2003","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Reddig J, Sieper J (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis Rheum 48:2224\u20132233","journal-title":"Arthritis Rheum"},{"key":"542_CR5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00042737-200304000-00003","volume":"15","author":"E Garcia-Planella","year":"2003","unstructured":"Garcia-Planella E, Domenech E, Esteve-Comas M, Bernal I, Cabre E, Boix J, Gassul MA (2003) Development of antinuclear antibodies and its clinical impact in patients with Crohn\u2019s disease treated with chimeric monoclonal anti-TNF-alpha antibodies (infliximab). Eur J Gastroenterol Hepatol 15:351\u2013354","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"542_CR6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","volume":"125","author":"S Vermeire","year":"2003","unstructured":"Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P (2003) Autoimmunity associated with anti-tumor necrosis factor \u03b1 treatment in Crohn\u2019s disease: a prospective cohort study. Gastroenterology 125:32\u201339","journal-title":"Gastroenterology"},{"key":"542_CR7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253\u2013259","journal-title":"N Engl J Med"},{"key":"542_CR8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1191\/0961203302lu236cr","volume":"11","author":"EG Favalli","year":"2000","unstructured":"Favalli EG, Sinigaglia L, Varenna M, Arnoldi C (2000) Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 11:753\u2013755","journal-title":"Lupus"},{"key":"542_CR9","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1. monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552\u20131563","journal-title":"Arthritis Rheum"},{"key":"542_CR10","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"RN Maini","year":"1999","unstructured":"Maini RN, St Clair EW, Breedveld FC, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Hamman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumor necrosis factor \u03b1. monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354:1932\u20131939","journal-title":"Lancet"},{"key":"542_CR11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","volume":"22","author":"M Bandt De","year":"2003","unstructured":"De Bandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O (2003) Anti-TNF-alpha-induced systemic lupus erythematosus. Clin Rheumatol 22:56\u201361","journal-title":"Clin Rheumatol"},{"key":"542_CR12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00054725-200305000-00005","volume":"9","author":"JB Klapman","year":"2003","unstructured":"Klapman JB, Ene-Stroescu D, Becker MA, Hananuer SB (2003) A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 9:176\u2013178","journal-title":"Inflamm Bowel Dis"},{"key":"542_CR13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(02)09800-8","volume":"360","author":"AK Mohan","year":"2002","unstructured":"Mohan AK, Edwards ET, Cot\u00e9 TR, Siegel JN, Braun MM (2002) Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 360:646","journal-title":"Lancet"},{"key":"542_CR14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","volume":"359","author":"N Shakoor","year":"2002","unstructured":"Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579\u2013580","journal-title":"Lancet"},{"key":"542_CR15","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.11033","volume":"48","author":"E Carlson","year":"2003","unstructured":"Carlson E, Rothfield N (2003) Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 48:1165\u20131166","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"542_CR16","first-page":"175","volume":"60","author":"MJ Bandt De","year":"2001","unstructured":"De Bandt MJ, Descamps V, Meyer O (2001) Two cases of etanercept-induced lupus-like syndrome in RA patients (abstract). Ann Rheum Dis 60(Suppl 1):175","journal-title":"Ann Rheum Dis"},{"key":"542_CR17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/40.11.1317","volume":"40","author":"GS Bleumink","year":"2001","unstructured":"Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BH (2001) Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 40:1317\u20131319","journal-title":"Rheumatology"},{"key":"542_CR18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2230.2003.01411.x","volume":"28","author":"VJ Swale","year":"2003","unstructured":"Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH (2003) Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 28:604\u2013607","journal-title":"Clin Exp Dermatol"},{"key":"542_CR19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/ard.61.11.1031","volume":"61","author":"AP Cairns","year":"2002","unstructured":"Cairns AP, Duncan MK, Hinder AE, Taggart AJ (2002) New onset of systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 61:1031\u20131032","journal-title":"Ann Rheum Dis"},{"key":"542_CR20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.7326\/0003-4819-131-8-199910190-00031","volume":"131","author":"PH Brion","year":"1999","unstructured":"Brion PH, Mittal-Henkle A, Kalunian KC (1999) Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 131:634","journal-title":"Ann Intern Med"},{"key":"542_CR21","first-page":"276","volume":"21","author":"L Lepore","year":"2003","unstructured":"Lepore L, Marchetti F, Facchini S, Leone V, Ventura A (2003) Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol 21:276\u2013277","journal-title":"Clin Exp Rheumatol"},{"key":"542_CR22","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1590-8658(03)00448-1","volume":"35","author":"P Sarzi-Puttini","year":"2003","unstructured":"Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, Carrabba M, Bianchi-Porro G (2003) Infliximab-induced lupus in Crohn\u2019s disease: a case report. Dig Liver Dis 35:814\u2013817","journal-title":"Dig Liver Dis"},{"issue":"Suppl 4","key":"542_CR23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1365-2036.1999.00027.x","volume":"13","author":"SB Hanauer","year":"1999","unstructured":"Hanauer SB (1999) Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 13(Suppl 4):16\u201322","journal-title":"Aliment Pharmacol Ther"},{"key":"542_CR24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0049-0172(95)80004-2","volume":"24","author":"CA Muhlen Von","year":"1995","unstructured":"Von Muhlen CA, Tan EM (1995) Antibodies in diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 24:232\u2013258","journal-title":"Semin Arthritis Rheum"},{"key":"542_CR25","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/9544","volume":"5","author":"MC Bickerstaff","year":"1999","unstructured":"Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Teenant GA, Bybee A, Mitchell DA, Cook HT, Butler PJ, Walport MJ, Pepys MB (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 5:694\u2013697","journal-title":"Nat Med"},{"key":"542_CR26","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1084\/jem.192.9.1353","volume":"192","author":"D Gershow","year":"2000","unstructured":"Gershow D, Kim S, Brot N, Elkon KB (2000) C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192:1353\u20131364","journal-title":"J Exp Med"},{"key":"542_CR27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/ard.61.4.358","volume":"61","author":"GF Ferraccioli","year":"2002","unstructured":"Ferraccioli GF, Mecchia F, Di Poi E, Fabris M (2002) Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 61:358\u2013361","journal-title":"Ann Rheum Dis"},{"key":"542_CR28","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E","volume":"43","author":"Y Ioannou","year":"2000","unstructured":"Ioannou Y, Isemberg DA (2000) Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43:1431\u20131442","journal-title":"Arthritis Rheum"},{"key":"542_CR29","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.4049\/jimmunol.167.12.6821","volume":"167","author":"CS Via","year":"2001","unstructured":"Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD (2001) In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 167:6821\u20136826","journal-title":"J Immunol"},{"key":"542_CR30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/331356a0","volume":"331","author":"CO Jacob","year":"1998","unstructured":"Jacob CO, McDevitt HO (1998) Tumor necrosis factor-\u03b1 in murine autoimmune \u2018lupus\u2019 nephritis. Nature 331:356\u2013358","journal-title":"Nature"},{"key":"542_CR31","first-page":"385","volume":"85","author":"K Mitamura","year":"1991","unstructured":"Mitamura K, Kang H, Tomita J, Hashimoto H, Sawada S, Horie T (1991) Impaired tumour necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 85:385\u2013391","journal-title":"Clin Exp Immunol"},{"key":"542_CR32","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/1529-0131(200011)43:11<2381::AID-ANR1>3.0.CO;2-M","volume":"43","author":"DS Pisetsky","year":"2000","unstructured":"Pisetsky DS (2000) Tumor necrosis factor \u03b1 blockers and the induction of anti-DNA antibodies. Arthritis Rheum 43:2381\u20132382","journal-title":"Arthritis Rheum"},{"key":"542_CR33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","volume":"2","author":"F Mackay","year":"2002","unstructured":"Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465\u2013475","journal-title":"Nat Rev Immunol"},{"key":"542_CR34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"542_CR35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood.V97.1.198","volume":"97","author":"B Nardelli","year":"2001","unstructured":"Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, Sosnovtseva S, Carrell JA, Feng P, Giri JG, Hilbert DM (2001) Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97:198\u2013204","journal-title":"Blood"},{"key":"542_CR36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9343(03)00390-5","volume":"115","author":"I Krause","year":"2003","unstructured":"Krause I, Valesini G, Scrivo R, Shoenfeld Y (2003) Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 115:390\u2013397","journal-title":"Am J Med"},{"key":"542_CR37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141\u2013147","journal-title":"N Engl J Med"},{"key":"542_CR38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00002018-200225030-00004","volume":"25","author":"R Fleischmann","year":"2000","unstructured":"Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A (2000) Safety and efficacy of disease-modifying anti-rheumatic agents. Drug Safety 25:173\u2013197","journal-title":"Drug Safety"},{"key":"542_CR39","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00003495-200262060-00003","volume":"62","author":"AA Drosos","year":"2002","unstructured":"Drosos AA (2002) Newer immunosuppressive drugs. Their potential role in rheumatoid arthritis therapy. Drugs 62:891\u2013907","journal-title":"Drugs"},{"key":"542_CR40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0889-857X(05)70136-8","volume":"26","author":"F Andrade","year":"2000","unstructured":"Andrade F, Casciola-Rosen L, Rosen A (2000) Apoptosis in systemic lupus erythematosus. Clinical implications. Rheum Dis North Am 26:215\u2013227","journal-title":"Rheum Dis North Am"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-004-0542-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-004-0542-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-004-0542-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:15:17Z","timestamp":1559042117000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-004-0542-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,31]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1007\/s00296-004-0542-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,31]]}}}